AI is transforming biomedical research, but meaningful advances in drug discovery require more than just increasingly powerful algorithms—they depend on combining machine learning with physics-based simulations, mechanistic models, and rigorous experimental validation. In this episode of Behind the Breakthroughs, Michael Antonov, co-founder of Oculus and computational drug discovery company Deep Origin, shares a pragmatic perspective on AI's opportunities and limitations in medicine, explaining where it is accelerating innovation and why human expertise and experimental science remain indispensable.
Produced and hosted by Jonathan D. Grinstein, PhD
Audio mixed and mastered by Erick Ziegler
Brought to you by Inside Precision Medicine (SAGE Publishing)
","author_name":"Inside Precision Medicine"}